Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice
Authors:
Preprint
- 7 July 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in mediating the therapeutic effects of these drugs remains unclear. In this study, we ethopharmacologically analyzed the role of 5-HT2A in the occurrence of anxiolytic-and antidepressant-like effects of serotonergic psychedelics such as psilocin, an active metabolite of psilocybin, DOI, and TCB-2 in mice. Mice with acute intraperitoneal psychedelic treatment exhibited significantly shorter immobility times in the forced swimming test (FST) and tail-suspension test (TST) than vehicle-treated control mice 24 h post-treatment. These effects were eliminated by pretreatment with volinanserin, a 5-HT2A antagonist. Surprisingly, the decreasing immobility time in the FST in response to acute psilocin treatment was sustained for at least three weeks. In the novelty-suppressed feeding test (NSFT), the latency to feed, an indicator of anxiety-like behavior, was decreased by acute administration of psilocin; however, pretreatment with volinanserin did not diminish this effect. In contrast, DOI and TCB-2 did not affect the NSFT performance in mice. Furthermore, psilocin, DOI, and TCB-2 treatment did not affect the spontaneous locomotor activity or head-twitch response, a hallucination-like behavior in rodents. These results suggest that 5-HT2A contributes to the antidepressant effects of serotonergic psychedelics rather than an anxiolytic effects.Keywords
All Related Versions
This publication has 54 references indexed in Scilit:
- The Tail Suspension TestJournal of Visualized Experiments, 2011
- Multiple receptors contribute to the behavioral effects of indoleamine hallucinogensNeuropharmacology, 2011
- Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in miceJournal of Psychopharmacology, 2010
- Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D ReportAmerican Journal of Psychiatry, 2009
- Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect BehaviorNeuron, 2007
- 1-Aminomethylbenzocycloalkanes: Conformationally Restricted Hallucinogenic Phenethylamine Analogues as Functionally Selective 5-HT2AReceptor AgonistsJournal of Medicinal Chemistry, 2006
- Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test–retest paradigm in miceBehavioural Brain Research, 2006
- Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of “Magic Mushroom”Journal of Natural Products, 2003
- Clinical and differential diagnostic aspects of treatment-resistant depressionJournal of Psychiatric Research, 1995
- Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana HeimCellular and Molecular Life Sciences, 1958